SPHRY 주가 차트
SPHRY 수입
Starpharma Holdings Limited
$4.68
-0.42%
$-0.02
종가: Jun 29, 16:00:00 GMT-4
$4.68
0%
$0
애프터마켓: Jun 29, 20:00:00 GMT-4
뒤로
Starpharma Holdings Limited (SPHRY) 수입
Earnings FAQ
SPHRY의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Starpharma Holdings Limited SPHRY의 지난 분기 매출 실적은 어땠나요?
Starpharma Holdings Limited의 매출 추정치는 얼마인가요?
Starpharma Holdings Limited의 수익 품질 점수는 얼마인가요?
Starpharma Holdings Limited는 언제 수익을 보고하나요?
Starpharma Holdings Limited의 예상 수익은 얼마인가요?
Starpharma Holdings Limited은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$4.7
시가
$4.25
일일 범위
$4.25 - $5.24
52주 범위
$0.55 - $5.7
거래량
2
평균 거래량
929
배당수익률
--
EPS(TTM)
-0.06
시가총액
$196.9M
Starpharma Holdings Ltd.란 무엇인가요?
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The firm's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The firm's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. The company also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The firm has applied its DEP technology to the innovative area of antibody-drug conjugates.
